Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis.
Journal
Metabolism open
ISSN: 2589-9368
Titre abrégé: Metabol Open
Pays: England
ID NLM: 101767753
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
11
05
2020
revised:
10
06
2020
accepted:
13
06
2020
entrez:
20
8
2020
pubmed:
20
8
2020
medline:
20
8
2020
Statut:
epublish
Résumé
We examined if empagliflozin was associated with modulation of cardiac autonomic tone among subjects with type 2 diabetes and stable coronary artery disease (CAD) relative to placebo. Using ambulatory 24-h Holter electrocardiographic data prospectively collected from a randomized trial, we compared changes in heart rate variability (HRV) parameters between empagliflozin- and placebo-assigned subjects over a follow-up period of 6 months. Measured HRV domains included: standard deviation (SD) of NN intervals (SDNN), SD of average NN intervals per 5-min (SDANN), root mean square of successive RR interval differences (RMSSD), % successive NN intervals differing >50 ms (ms) (pNN50), low frequency (LF), high frequency (HF) and the LF/HF ratio (LF:HF). Differences in HRV parameters between the 2 groups were compared with analysis of covariance (ANCOVA). Statistical measures of significance were reported as adjusted differences between the 2 groups and their corresponding 95% confidence intervals. Sixty-six subjects completed 24-h Holter monitoring at baseline and 6-months. Over 6 months, the change in HRV was similar between subjects treated with empagliflozin vs. placebo for the following parameters: RMSSD -1.2 ms (-6.0 to 3.6 ms); pNN50 0.5% (-2.6 to 3.6%); VLF -907.8 ms Compared to placebo, empagliflozin did not result in changes in autonomic tone among individuals with type 2 diabetes and stable coronary artery disease.
Identifiants
pubmed: 32812924
doi: 10.1016/j.metop.2020.100039
pii: S2589-9368(20)30019-0
pii: 100039
pmc: PMC7424781
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100039Informations de copyright
© 2020 Published by Elsevier Inc.
Références
Cell Metab. 2019 Oct 1;30(4):609-613
pubmed: 31477497
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
J Cardiol. 2018 May;71(5):471-476
pubmed: 29415819
JACC Basic Transl Sci. 2019 Feb 25;4(1):27-37
pubmed: 30847416
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
J Am Coll Cardiol. 2009 Jul 28;54(5):375-85
pubmed: 19628111
PLoS One. 2016 Aug 23;11(8):e0161648
pubmed: 27551828
Circulation. 2019 Nov 19;140(21):1693-1702
pubmed: 31434508
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
JACC Basic Transl Sci. 2017 Aug 04;2(4):347-354
pubmed: 30062155
PLoS One. 2016 Mar 10;11(3):e0150756
pubmed: 26963613
Am J Cardiol. 1987 Feb 1;59(4):256-62
pubmed: 3812275
Circulation. 1996 Mar 1;93(5):1043-65
pubmed: 8598068
Cardiovasc Res. 2018 Feb 1;114(2):336-346
pubmed: 29016744
JACC Basic Transl Sci. 2020 Feb 24;5(2):180-182
pubmed: 32142070
Circ Res. 2018 Feb 16;122(4):624-638
pubmed: 29449364
Diabetes Ther. 2018 Oct;9(5):2107-2116
pubmed: 30097993
Eur Heart J. 2003 Sep;24(17):1560-6
pubmed: 12927191
Prog Cardiovasc Dis. 2008 May-Jun;50(6):404-19
pubmed: 18474284
Circulation. 2020 Feb 25;141(8):704-707
pubmed: 31707794
Drug Discov Ther. 2018 Mar 19;12(1):51-54
pubmed: 29479047
J Clin Hypertens (Greenwich). 2006 May;8(5):330-5
pubmed: 16687941
Diabetologia. 2018 Oct;61(10):2108-2117
pubmed: 30132036
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
JACC Basic Transl Sci. 2018 Aug 26;3(5):575-587
pubmed: 30456329
JACC Basic Transl Sci. 2019 Oct 23;4(7):831-840
pubmed: 31998851
JACC Basic Transl Sci. 2020 Jan 29;5(2):169-179
pubmed: 32140623